Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNF-alpha-armed NY-ESO-1 T-cell receptor T cells
- Development stage
- Preclinical
- Lead developer
- University of California, Los Angeles
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
TNF-alpha-armed NY-ESO-1 T-cell receptor T cells are an investigational adoptive cell therapy consisting of autologous T cells engineered via lentiviral transduction to express both a T-cell receptor (TCR) specific for the NY-ESO-1 (New York esophageal squamous cell carcinoma 1) cancer-testis antigen and a supplemental copy of the tumor necrosis factor-alpha (TNF-α) gene. This "arming" strategy is designed to overcome the immunosuppressive tumor microenvironment (TME) characteristic of solid tumors. Upon recognition of NY-ESO-1 presented by HLA-A*02:01, these T cells secrete TNF-α locally in an antigen-dependent manner. This localized cytokine secretion promotes T-cell infiltration, reduces the presence of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), and enhances anti-tumor effector activity without inducing the systemic toxicity typically associated with TNF-α administration. Preclinical studies have demonstrated superior tumor control and survival in melanoma models compared to conventional TCR-T cells.
- Other names
- TNF-alpha-secreting NY-ESO-1 TCR-T cellsTNF-a-armed NY-ESO-1 TCR-T cells
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on TNF-alpha-armed NY-ESO-1 T-cell receptor T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNF-alpha-armed NY-ESO-1 T-cell receptor T cells.